Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8117468 | 0.86 | MAPT (0.67) | MAPTKDM4EMAPK1 | |
| SCHEMBL10245285 | 0.84 | MAPT (0.53) | MAPTKDM4EMAPK1 | |
| SCHEMBL19895769 | 0.83 | SIGMAR1 (0.69) | KDM4EALDH1A1 | |
| SCHEMBL22642436 | 0.80 | MAPT (0.61) | MAPTKDM4EMAPK1 | |
| SCHEMBL19231628 | 0.80 | KDM4E (0.51) | MAPTKDM4EMAPK1 | |
| SCHEMBL8725812 | 0.79 | SIGMAR1 (0.75) | KDM4E | |
| SCHEMBL5319459 | 0.78 | HRH3 (0.74) | MAPTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL8744995 | 0.77 | ITGB3 (0.50) | KDM4EALDH1A1 | |
| SCHEMBL3331268 | 0.77 | MAPT (0.57) | MAPTKDM4EMAPK1 | |
| SCHEMBL13869588 | 0.77 | ALDH1A1 (0.69) | MAPTKDM4EMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | MAPT 2362/4885KDM4E 1071/4885MAPK1 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.